Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems

Abstract

Biomimetic delivery systems (BDSs), inspired by the intricate designs of biological systems, have emerged as a groundbreaking paradigm in nanomedicine, offering unparalleled advantages in therapeutic delivery. These systems, encompassing platforms such as liposomes, protein-based nanoparticles, extracellular vesicles, and polysaccharides, are lauded for their targeted delivery, minimized side effects, and enhanced therapeutic outcomes. However, the translation of BDSs from research settings to clinical applications is fraught with challenges, including reproducibility concerns, physiological stability, and rigorous efficacy and safety evaluations. Furthermore, the innovative nature of BDSs demands the reevaluation and evolution of existing regulatory and ethical frameworks. This review provides an overview of BDSs and delves into the multifaceted translational challenges and present emerging solutions, underscored by real-world case studies. Emphasizing the potential of BDSs to redefine healthcare, we advocate for sustained interdisciplinary collaboration and research. As our understanding of biological systems deepens, the future of BDSs in clinical translation appears promising, with a focus on personalized medicine and refined patient-specific delivery systems.

Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine

“…Furthermore, they offer the potential for enhanced consistency in quality control standards across different production batches, which is a critical consideration in the context of biological drug development [ 5 ]. However, the path to clinical application of these vesicles is fraught with complexities, necessitating a comprehensive elucidation of their biological mechanisms, the establishment of scalable production methodologies that ensure reproducibility, and a tangible enhancement of their intrinsic therapeutic potential [ 21 ]. A primary challenge in this developmental trajectory is the establishment of uniform manufacturing protocols that guarantee consistency across product batches.…”

The Optimization Design of Macrophage Membrane Camouflaging Liposomes for Alleviating Ischemic Stroke Injury through Intranasal Delivery

“…Cell membrane-coated nanomaterials have become a new and promising nanotechnology [ 32 , 33 ]. This biomimetic nano delivery system’s uniqueness lies in its ability to utilize affinity ligands on the cell membrane to achieve targeted therapy for diseases, thereby improving its therapeutic effect [ 34 , 35 ]. For example, macrophage membrane-coated liposomes can play an important role in targeted drug delivery; these stealth liposomes allow liposomal cloaking into macrophage membranes and can protect the liposomes from phagocytic uptake by the immune cells, whereas the surface-wrapped macrophage membranes allow for the recognition of antigens and target inflamed tissues [ 36 ].…”

Emerging Trends and Translational Challenges in Drug and Vaccine Delivery

“…Wang et al in their recent review discussed the translational challenges and prospective solutions for implementing biomimetic delivery systems (BDSs) for therapeutic delivery [ 9 ]. BDSs are based on complex designs of biological structures and have emerged as a powerful tool for drug and vaccine delivery.…”